Last reviewed · How we verify
lenalidomide, bortezomib and dexamethasone
This three-drug combination works by enhancing immune cell activity (lenalidomide), inhibiting proteasome function to trigger cancer cell death (bortezomib), and suppressing inflammation (dexamethasone) to treat multiple myeloma.
This three-drug combination works by enhancing immune cell activity (lenalidomide), inhibiting proteasome function to trigger cancer cell death (bortezomib), and suppressing inflammation (dexamethasone) to treat multiple myeloma. Used for Multiple myeloma (newly diagnosed and relapsed/refractory).
At a glance
| Generic name | lenalidomide, bortezomib and dexamethasone |
|---|---|
| Also known as | Revlimid™, Velcade®, and Decadron |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Drug class | Combination therapy: immunomodulatory agent, proteasome inhibitor, and corticosteroid |
| Target | Multiple targets: cereblon (lenalidomide), 20S proteasome (bortezomib), glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activity while promoting tumor necrosis factor production. Bortezomib is a proteasome inhibitor that causes accumulation of misfolded proteins leading to apoptosis in myeloma cells. Dexamethasone is a corticosteroid that provides anti-inflammatory and anti-myeloma effects. Together, these agents provide synergistic activity against multiple myeloma cells.
Approved indications
- Multiple myeloma (newly diagnosed and relapsed/refractory)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Peripheral neuropathy
- Infection
- Fatigue
- Diarrhea
- Nausea
- Hyperglycemia
- Insomnia
Key clinical trials
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (PHASE3)
- A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) (PHASE4)
- A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (PHASE3)
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (PHASE2)
- Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: